WGRX: 8-K · delisting
DataMeds AI (NASDAQ: MEDS) announced it received written notice from Nasdaq dated October 19, 2026 confirming it has regained compliance with Listing Rule 5550(b)(1), the $2.5 million minimum stockholders' equity requirement. The company had been in deficiency status since an April 13, 2026 letter, when its stockholders' equity stood at negative $(12,447,801) per its FY2025 10-K; it had also previously cured a $1.00 bid-price deficiency in June 2026. Compliance was regained after 8-K filings on October 13 and 16, 2026 confirmed stockholders' equity exceeded $2.5 million. However, the company warns that if it fails to evidence continued compliance in its next periodic report, it may again face delisting.
WGRX: 8-K · material agreement
DataMeds AI entered an exclusive IP license with REBOOT Health AI on October 13, 2026, licensing the REBOOT Health AI Platform as the reconfigured 'DataMeds Platform' for managing GLP-1 users in its direct-to-consumer weight management business. As consideration, DataMeds issued REBOOT 666,667 shares valued at $2,000,000, with a true-up mechanism requiring additional shares if the market value falls below $2 million after 180 days, plus a $50,000 payment and an ongoing revenue share on Adjusted Gross Revenue. The same filing updates the Nasdaq listing deficiency disclosed in April 2026, when stockholders' equity of negative $12.4 million fell below the $2.5 million minimum. Since then, the company converted roughly $1.5 million of vendor payables to equity, extinguished about $18.7 million of debt via settlement, acquired Helomics, and issued the REBOOT shares — and now believes its stockholders' equity exceeds $2.5 million. Compliance is not yet confirmed: Nasdaq has not formally verified the cure, and failure to demonstrate the requirement at the next periodic report could trigger delisting proceedings. The perpetual license also carries minimum revenue thresholds and excludes B2B healthcare use of the REBOOT platform.
WGRX: 8-K · litigation
DataMeds AI, Inc. (Nasdaq: MEDS) settled dueling lawsuits over its May 2023 Membership Interest Purchase Agreement, paying $450,000 to the Settling Parties including Brian Norton, Nomad Capital and Strategix Global. Of that payment, $350,000 covered the repurchase and extinguishment of 364,099 shares of common stock and $100,000 settled the MIPA and all released claims. As a result of the settlement, the Company extinguished approximately $19 million in liability that appeared on its consolidated balance sheet, and it confirmed stockholders' equity now exceeds $2,500,000 as of October 13, 2026. Separately, on October 13, 2026 the Company licensed a care management platform from REBOOT Health AI, Inc. to integrate into its business model, issuing 666,667 shares of common stock to REBOOT as consideration.
WGRX: S-1/A · offering registration
DataMeds AI (Nasdaq: MEDS) filed an S-1/A registering up to 34,462,057 shares for resale by selling stockholders — roughly 7.6 times its 4,515,862 shares outstanding as of September 28, 2026. The company receives no proceeds; shares stem from a $21.1M convertible note PIPE (May 2026, 20% OID), PIPE/PA warrants, and prior private issuances. The convertible notes and Series A Preferred carry variable-price conversion at market with floors of $1.00 (or lower post-Mandatory Conversion Date), meaning dilution expands as the stock falls — at a $1.00 conversion price, note conversion alone represents ~55.1% dilution, rising to ~75.3% with full warrant exercise. The stock traded between $0.85 and $6.07 in the month before filing, closing at $2.88 on October 7, 2026. Effectiveness is conditioned on stockholder approval of a blank-check preferred amendment and filing of a Series A Preferred certificate of designation, which are still pending. The filing also discloses a pending Helomics AI diagnostics acquisition, a proposed transaction with Scilex, Datavault AI and EOS, a 1-for-50 reverse split in May 2026, and a Nasdaq stockholders'-equity compliance deadline of October 12, 2026.
DataMEDS AI, Inc. entered into a settlement agreement and release on September 11, 2026 with Brian Norton, the Madsen family parties, RxERP, Nomad Capital and Strategix, ending dueling lawsuits in Florida state court and the Delaware Court of Chancery that arose from the May 2023 Membership Interest Purchase Agreement. Under the agreement, both cases will be dismissed with prejudice and the parties exchanged mutual releases of claims. The Company paid $450,000 in total, with $350,000 attributed to the repurchase and extinguishment of 364,099 shares of its common stock and $100,000 as consideration for the compromise and settlement of the MIPA and all other released claims. As a result of the settlement, DataMEDS anticipates extinguishing approximately $19 million in liability that appears on its consolidated balance sheet, a substantial de-risking for the small-cap filer given the modest cost of resolution.
WGRX: 8-K · acquisition merger
On September 11, 2026, DataMeds AI, Inc. (Nasdaq: MEDS) closed its acquisition of Helomics Corporation, purchasing all outstanding shares from seller Axe Compute Inc. under a stock purchase agreement; Helomics became a wholly owned subsidiary of DataMeds. Consideration comprised 636,328 DataMeds shares, approximately 19.99% of shares outstanding immediately before the deal, plus a convertible promissory note with an original principal of $1,363,672.00 that accrues 7% simple interest, matures September 11, 2029, and converts at $1.00 per share. The note automatically converts once stockholders approve the issuance, which DataMeds must put to a vote within 75 days of closing under Nasdaq Rule 5635(d); the note carries full-ratchet anti-dilution protection, and the seller is locked up for 12 months and bound by a six-month voting agreement. For a micro-cap with 3,197,633 shares outstanding at signing, the transaction is transformative: full conversion would take total shares issued to roughly 2.0 million, implying about $2 million of aggregate consideration, in exchange for adding an FDA- and CLIA-regulated laboratory business to the company.
WGRX: 8-K · earnings release
DataMeds AI (Nasdaq: MEDS, formerly Wellgistics Health/WGRX) reported Q2 2026 net revenues of $1.78 million, up 14% sequentially and ahead of management projections, but the quarter carried a net loss of $18.36 million ($7.13 per share) versus $6.67 million a year ago, driven largely by an $8.88 million loss on debt extinguishment and higher G&A. Revenue remains down sharply from the prior-year quarter's $7.79 million. The balance sheet was repaired mainly through new issuance: cash rose to $2.46 million following a $6.5 million June 2026 raise and the restructuring of $14.5 million in legacy debt, but total liabilities of $52.26 million now exceed total assets of $32.76 million, leaving a stockholders' deficit of roughly $19.5 million. Management is betting on a turnaround: a 1:50 reverse split in May 2026 partially addressed Nasdaq delisting risk, holders of about 49% of shares signed 90-plus-day lock-ups, and the Health Lives Here app with NFL Alumni Health is slated to launch in September 2026 targeting rural GLP-1 patients through independent pharmacies, alongside a pending IP consolidation with Datavault AI (DVLT), Scilex Holdings (SCLX) and others. A Dream Bowl Meme Coin distribution of 50 tokens per share is set for September 9, 2026; with heavy convertible debt against thin cash, execution on the app launch and the Datavault Transaction closing are the key near-term catalysts for the equity.
WGRX: 10-Q · periodic report
DataMeds AI, Inc. (formerly Wellgistics Health, Inc., now trading as MEDS on Nasdaq) filed its Q2 2026 10-Q reporting a net loss of $18.4 million on net revenues of $1.78 million, down roughly 77% from $7.79 million a year earlier, driven by a collapse in its pharmaceutical distribution business. Management raised substantial doubt about the Company's ability to continue as a going concern. The balance sheet is severely stressed: cash of $2.46 million against total debt of $31.8 million and a stockholders' deficit of $19.5 million. The quarter included an $8.9 million loss on debt extinguishment from a May 2026 refinancing into $20.3 million of 0% convertible notes carrying a 20% original issue discount, and a 1-for-50 reverse stock split became effective May 26, 2026 after a prior bid-price compliance issue. Nasdaq granted the Company until October 12, 2026 to evidence compliance with the $2.5 million minimum stockholders' equity rule, failing which its common stock may be delisted. A major dilution overhang exists, with 29.8 million potentially dilutive shares from warrants and convertible notes versus roughly 3.06 million shares outstanding, and executive warrants were repriced from $0.50 to $0.005. A pending transaction under a July 29, 2026 Amended and Restated LOI with EOS Technology Holdings, Scilex Holding, Datavault AI, and HealthBridge Advisors would issue acquisition stock leaving those parties with approximately 84.6% and Fortitude Advisors roughly 5.0%, leaving existing public holders with only about 10.4% on a fully diluted basis — subject to definitive agreements, stockholder approvals, and Nasdaq requirements.
WGRX: 8-K · dividend
DataMEDS AI, Inc. filed an 8-K on August 14, 2026 announcing that its licensing partner Datavault AI Inc. will make a voluntary one-time distribution of Dream Bowl 2026 Meme Coin tokens to DataMEDS common stockholders of record as of the close of business on August 7, 2026, at a ratio of 50 Meme Coins per share. Payment begins September 9, 2026, and the stated fair market value is $0.01 per Meme Coin as of August 7, 2026 per Biconomy.com, implying roughly $0.50 of token value per DataMEDS share at the valuation date. Holders must set up a Datavault digital wallet and submit an Opt-In Agreement via dreambowlcoin.com to receive the tokens. Key caveats: Datavault's board can change the dates or revoke the distribution entirely before payment, the tokens confer no equity, dividend, or profit rights and may become worthless, the election is irrevocable, and the in-kind distribution may be treated as a dividend to the extent of DataMEDS's earnings and profits for tax purposes.
WGRX: NT 10-Q · late filing
DataMEDS AI, Inc. filed a Form 12b-25 (NT 10-Q) on August 14, 2026 notifying the SEC that it cannot timely file its Quarterly Report on Form 10-Q for the quarter ended June 30, 2026, which was due the same day. The company said it requires additional time to complete the preparation and review of its financial statements and related disclosures, and expects to file the Form 10-Q within the five-calendar-day extension period permitted under Rule 12b-25. Chief Financial Officer Eric Sherb signed the notification, confirmed that all other required periodic reports were filed over the preceding 12 months, and stated the company does not anticipate a significant change in results of operations versus the year-ago period. Because generic preparation delays can precede deeper accounting or internal-control issues, the actual 10-Q and any follow-on disclosures warrant close monitoring.
WGRX: S-1 · offering registration
DataMeds AI, Inc. (formerly Wellgistics Health, Inc.; Nasdaq: MEDS) filed an S-1 registering up to 34,462,058 shares of common stock for resale by selling stockholders, a count more than 12 times its 2,847,198 shares outstanding as of July 27, 2026. The company is selling no shares and will receive no proceeds from these resales. The registered shares trace mainly to a May 2026 PIPE: $21,132,812.50 of 0% convertible notes sold at a 20% original issue discount for $16,906,250 in cash, convertible at the lesser of $6.00 or the prior-day close with a $1.00 floor, plus 8,298,225 PIPE warrants at $7.50 and placement agent warrants issued to Dawson James Securities. The company itself discloses that conversion of the notes at $3.12 (the July 27 close) would mean approximately 70.4% dilution, rising to 92.1% at the $1.00 floor, with the stock last reported at $2.80 on August 5, 2026. The proposed Series A Preferred adds 10% annual dividends that accrue into stated value, compounding dilution over time. The backdrop heightens the risk: DataMeds effected a 1-for-50 reverse split in May 2026, remains under a Nasdaq stockholders' equity compliance plan through October 12, 2026, and has operated under an interim co-CEO since May 2026.
DataMEDS AI, Inc. (formerly Wellgistics Health) entered into an Amended and Restated Letter of Intent dated July 29, 2026 to acquire QLPM-related intellectual property from EOS Technology Holdings and Scilex Holding, exclusively license Datavault AI Health, and acquire a controlling interest in Tollo Health, paying entirely in common stock with no preferred or convertible securities as deal consideration. Upon closing, EOS, Scilex, Datavault and HealthBridge Advisors would own approximately 84.6% of the company combined (19.9% each for the first three and 24.9% for HBA), with Fortitude Advisors at roughly 5% and existing public stockholders left with only about 10.4% on a fully diluted target basis — a change-of-control-level dilution event. Binding terms include a minimum $2 million Immediate Capital investment concurrent with signing, an At-The-Market facility filing within 14 days, exclusivity through September 30, 2026, the immediate appointment of Gerald Commissiong as Interim Co-CEO, and Dan Hirsch as Interim VP of Finance. Closing remains conditional on definitive agreements, a fairness opinion, stockholder approval and Nasdaq approvals — including a potential initial listing application if treated as a change of control under Listing Rule 5110(a) — and contemplates a reverse stock split to maintain the Nasdaq listing.
WGRX: 8-K · other
DataMeds AI updated the record date for the distribution of the Dream Bowl 2026 Meme Coin to August 7, 2026. The company also increased the distribution ratio to 50 coins per share of common stock held, up from a previously announced one-to-one ratio. DataMeds reported 2,847,198 common shares outstanding as of the press release date. Approximately 1,533,930 shares, representing a majority of the outstanding stock, are subject to lock-up agreements preventing sale for at least 90 days. The distribution will be coordinated with DataVault AI, Inc. and requires stockholders to provide digital wallet information. The company also noted 80,826 cash warrants are currently outstanding with an exercise price of $35.00 per share.
DataMEDS AI Officially Begins Trading Under Stock Symbol 'MEDS' on the NASDAQ Capital Markets
DataMEDS AI (formerly Wellgistics Health) has completed its corporate rebranding and commenced trading on the NASDAQ Capital Market under the new ticker symbol 'MEDS'. The company's strategy focuses on leveraging its EinsteinRx AI and PharmacyChain blockchain platforms to target GLP-1 and Long COVID patient bases through data monetization and clinical trial offerings. As of the release date, the company reported 2.85 million shares outstanding with a public float of approximately 919,465 shares, while majority shareholders representing 1.53 million shares have entered into 90-day lock-up agreements.
WELLGISTICS HEALTH, INC. OFFICIALLY CHANGES CORPORATE NAME TO DATAMEDS AI, INC.
Wellgistics Health, Inc. has officially changed its corporate name to DataMEDS AI, Inc., effective immediately, and will begin trading under the new ticker symbol 'MEDS' on the NASDAQ Capital Market starting July 22, 2026. The rebranding reflects the company's strategic focus on integrating its EinsteinRx AI platform and PharmacyChain blockchain technology to create a vertically aligned healthcare ecosystem. Management aims to utilize the Health Lives Here app to consolidate electronic health data, allowing patients to participate in data transaction revenue and enabling tailored clinical trial offerings.
Wellgistics Health Announces Updated Record Date for Distribution of Dream Bowl 2026 Meme Coin to Stockholders
Wellgistics Health announced an updated record date of July 31, 2026 for the distribution of the Dream Bowl 2026 Meme Coin to its stockholders. Eligible Wellgistics shareholders will receive 50 coins per share, an increase from the previously announced ratio of one coin per share. DataVault AI (DVLT) is named as the partner coordinating the determination of the final distribution date.
Rubenstein Public Relations Named Agency of Record for Wellgistics Health, Inc.
Wellgistics Health has retained Rubenstein Public Relations as its agency of record to manage communications during a planned corporate reorganization. The company is preparing to launch the Health Lives Here mobile application and expand its EinsteinRx AI platform into medical and laboratory fields. Wellgistics currently operates a blockchain-enabled platform that connects over 6,500 pharmacies and 200 manufacturers for prescription routing and wholesale distribution.
Wellgistics Health Appoints Brett Thompson as Chief Technology Officer
Wellgistics Health appointed Brett Thompson as consulting Chief Technology Officer, succeeding Srini Kalla who stepped down from the role. Thompson brings over 30 years of experience in enterprise software and health IT, specifically focused on pharmacy technology and healthcare interoperability. The company is currently transitioning its brand to DataMeds AI, centered on integrating its EinsteinRx and PharmacyChain platforms.
Wellgistics Health Executive Chairman and President Exercise Warrants
DataMeds AI, Inc. Selected as Proposed New Name for Wellgistics Health, Inc.
Wellgistics Health announced a proposed corporate name change to DataMeds AI, Inc. and a corresponding ticker change to MEDS, pending shareholder approval. The company simultaneously rebranded its pharmacy division to Corexa Health as it integrates operations from proposed partners including DataVault AI and Scilex Pharma. Management detailed current capitalization, noting 2.65 million shares outstanding with approximately 1.33 million shares locked up for 90 days.
WGRX: PRE 14A · proxy statement
Wellgistics Health is soliciting stockholder approval to change its corporate name to DataMeds AI, Inc. and its ticker symbol to MEDS. The Board states that the new name better aligns with the company's strategic focus as a healthcare technology and pharmaceutical services platform. The filing also includes a proposal to authorize 1,000,000 shares of blank check preferred stock to provide financial and strategic flexibility for future transactions. Stockholders are asked to approve an amendment to the 2023 Equity Incentive Plan that increases the annual share reserve from 3% to 20% of outstanding shares and reserves 6,000 shares of super-voting preferred stock for issuance. The company further proposes designating a Series A Super-Voting Preferred Stock with 10,000 votes per share to be issued to directors and executive officers. The Board believes these measures will support long-term strategic objectives and provide voting stability. The annual meeting agenda includes the election of five directors: Prashant Patel, Suren Ajjarapu, Donald Fell, Gary Herman, and Marlene Velez. Additionally, the Board recommends the ratification of Suri & Co., Chartered Accountants as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
Wellgistics Health (WGRX) received a Nasdaq extension to avoid delisting due to negative stockholders' equity of $12.4 million, which violates the $2.5 million minimum requirement. The company has until October 12, 2026, to demonstrate compliance, primarily through a proposed merger with DataVault AI and acquisition of Tollo Health, which it claims will result in $40 million in equity and $4 billion in assets. Separately, the company resolved a second compliance issue regarding its stock price. Nasdaq confirmed that WGRX regained compliance with the $1.00 minimum bid price requirement as of June 8, 2026, closing that matter. However, failure to meet the equity compliance deadline by October will still result in delisting proceedings.
WGRX: 8-K/A · offering registration
Wellgistics Health, Inc. filed Amendment No. 2 to its Current Report on Form 8-K to replace and refile Exhibit 4.3, which contains the Form of Placement Agent Warrant. The company stated that this amendment does not modify or update any other disclosures in the original report or previous amendments, nor does it reflect any new events. The warrant exhibit discloses an exercise price of $7.50 per share and a 150% warrant coverage on the face value of the associated note. The warrants expire on May 27, 2031, and include standard provisions for cashless exercise, mandatory exercise under specific volume and price conditions, and beneficial ownership limitations of 4.99% or 9.99%. This filing is purely administrative in nature, correcting a previously filed exhibit without introducing new material information regarding the company's operations, financial condition, or capital structure.
WGRX: 8-K/A · debt financing
Wellgistics Health filed an amendment to its 8-K to include omitted exhibits detailing a completed $21 million convertible debt refinancing. The transaction provides $6.5 million in fresh capital and refinances all outstanding convertible debt, satisfying a key closing condition for the DelivMeds AI partnership. The new debt converts into common stock at $6.00 per share and includes an automatic exchange provision into Preferred Stock at $50.00 per share upon registration effectiveness and shareholder approval. This structure signals strong investor confidence but introduces significant potential dilution for existing shareholders. The capital raise enables the company to proceed with its vertically-integrated growth strategy and the DelivMeds AI transaction, removing a major execution risk. However, the high conversion prices and dilution potential warrant close monitoring of future equity issuances.
Wellgistics Health Provides Mid-Year 2026 Corporate Outlook
Wellgistics Health outlined its mid-year 2026 strategy, focusing on closing the DelivMeds AI transaction and launching the Health Lives Here app in Q3 2026. The company confirmed that recent capital raises and debt restructuring provide liquidity through late 2026, with potential extension to 2029 if embedded warrants are exercised. A new lock-up agreement limits the float to approximately 1.3 million shares, reducing sell-side pressure while new shares await registration for resale in Q3.
WGRX: 8-K · debt financing
Wellgistics Health, Inc. (WGRX) closed a $16.9 million private placement of convertible promissory notes and warrants on May 27, 2026. The notes have an aggregate principal value of $21.1 million, reflecting a 20% original issue discount, and bear 0% interest with a one-year maturity. The offering includes warrants with 150% coverage exercisable at $7.50 per share, which could generate up to $42.8 million in additional proceeds if fully exercised. The company used a portion of the proceeds to repay $1.77 million in debt owed to Marco Capital, Inc. Holders of a majority of outstanding shares entered into lock-up agreements restricting sales for 90-180 days. The notes will automatically convert into Series A Convertible Preferred Stock upon the effectiveness of a resale registration statement and stockholder approval, introducing significant dilution risk and complex capital structure changes.
Wellgistics Health Announces Lock-Up Agreement with Holders of a Majority of its Common Stock
Wellgistics Health announced that holders of 1,333,930 common shares, representing a majority of outstanding shares, have entered into a lock-up agreement. The agreement precludes the sale of these shares into the market for at least 90 days. Interim Co-CEO Gerald Commissiong stated the move underscores shareholder confidence in management’s ability to execute the vertically-integrated growth plan and recent restructuring of convertible liabilities.
Wellgistics Health Refinances Outstanding Convertible Debt and Raises $6.5M
Wellgistics Health completed a $21 million convertible debt offering that refinances all outstanding debt and raises $6.5 million in new capital. The new debt converts into common shares at $6.00 per share, but includes an automatic exchange provision into Preferred Stock that converts at $50.00 per share upon registration and shareholder approval. This financing satisfies a closing condition for the DelivMeds AI transaction with Datavault AI, EOS Technology Holdings, Scilex Pharma, and HealthBridge Advisors, but carries substantial dilution risk for existing common shareholders.
Wellgistics Health Completes Reverse Split
Wellgistics Health completed a 1-for-50 reverse stock split of its common shares effective May 26, 2026. The split reduced the outstanding share count from approximately 125.7 million to 2.5 million shares. The company stated the move is intended to increase the per-share trading price to regain compliance with Nasdaq's minimum bid price requirement.
Wellgistics Health Releases Letter to Our Shareholders
Wellgistics Health released a shareholder letter detailing a strategic pivot toward vertical integration and blockchain-based healthcare infrastructure. The company announced a binding term sheet with Datavault AI to integrate its EinsteinRx AI platform with Datavault’s PharmacyChain blockchain technology, aiming to create a unified data fabric for healthcare. Additional moves include forming DelivMeds AI, acquiring the QOLPOM patent portfolio for biometric verification, and taking a controlling interest in Tollo Health to engage GLP-1 patients directly. Management describes these transactions as the most consequential in the company's history, positioning the pharmacy as the central node for data capture and patient engagement.
Why Wellgistics Health (WGRX) Stock Fell Over 24% After Hours?
Wellgistics Health Announces Reverse Stock Split
Wellgistics Health announced a 1-for-50 reverse stock split effective May 26, 2026, to regain compliance with Nasdaq's minimum bid price requirement. The split will reduce outstanding shares from approximately 125.7 million to 2.5 million, with fractional shares rounded up to the nearest whole share. The extreme 1-for-50 ratio signals significant distress regarding the company's listing status and likely downward pressure on liquidity and investor confidence.
Wellgistics Health and Datavault AI to Form DelivMeds AI via PharmacyChain™ License Expansion and Acquisitions of QOLPOM Biometric Health Data and Drone Logistics IP and Majority of Tollo Health
Datavault AI (DVLT) signed a binding term sheet with Wellgistics Health (WGRX) to form DelivMeds AI, a new healthcare entity with an estimated $4 billion in combined assets. The deal combines Wellgistics’ pharmacy network and EinsteinRx AI with Datavault’s blockchain infrastructure, plus acquired IP from Scilex (SCLX) and EOS for biometric drone delivery. Datavault also acquired a controlling stake in Tollo Health, adding medical foods for GLP-1 side effects and the 'Health Lives Here' consumer app, launching a pilot in North Carolina in July 2026.
Wellgistics Health Reports First Quarter 2026 Financials and Provides Business Update
Wellgistics Health, Inc. (WGRX) filed an 8-K on May 18, 2026, to announce the withdrawal of its Preliminary Proxy Statement on Schedule 14A that was previously filed on May 14, 2026. The company stated that it determined not to proceed with the preliminary proxy materials in their current form as it continues to evaluate potential strategic transactions. No definitive proxy materials were distributed or mailed to stockholders, and the company noted it may file revised proxy materials at a later date.
Wellgistics Health, Inc. filed a Form 12b-25 notification on May 15, 2026, stating it cannot file its Quarterly Report on Form 10-Q for the period ended March 31, 2026, by the prescribed deadline. The company cited the need for additional time to complete the preparation and review of its financial statements and related disclosures as the reason for the delay. Management expects to file the report within the five-calendar-day extension period allowed under Rule 12b-25, but the inability to close books on time raises concerns about internal controls or accounting complexity.
Wellgistics Health to Announce First Quarter 2026 Financials on Tuesday May 19, 2026
Wellgistics Health will report first quarter 2026 financial results on Tuesday, May 19, 2026. The release contains no specific financial data, guidance, or operational metrics, serving solely as a scheduling notice for the upcoming earnings call. Forward-looking statements mention a proposed acquisition of WellCare Today, LLC, but note that definitive agreements have not been signed and the transaction is subject to significant risks and approvals.
Wellgistics Health Accelerates Digital Health Expansion of its Newly Announced RPM, RTM and CCM Pilot with Planned Acquisition of WellCare Today and its Proprietary Samsung Galaxy Watch Care Monitoring Program
Wellgistics Health signed a non-binding letter of intent to acquire WellCare Today for approximately $15 million, aiming to expand its digital health capabilities. The deal includes a $3 million cash payment with the remainder structured as a performance-based earnout in preferred stock, linking future value to execution success. WellCare Today brings the HealthAssist platform, which uses Samsung Galaxy Watches for remote patient monitoring (RPM) and chronic care management (CCM), integrating with Wellgistics' network of 6,500+ pharmacies.
Wellgistics Health Announces Pilot MSO Collaboration with Kare PharmTech Targeting $14 Billion U.S. Market for CCM and RPM Services
Wellgistics Health announced a pilot MSO collaboration with Kare PharmTech and Kare Clinicals to integrate chronic care management and remote patient monitoring services. The initiative targets the $14 billion U.S. RPM market, leveraging Wellgistics' network of over 6,500 independent pharmacies, and has generated 1,500+ claims to date. Management highlighted the potential for new revenue streams and improved patient outcomes, though the company noted the pilot is exploratory with no assurance of material revenue.
WGRX: 8-K/A · material agreement
Wellgistics Health, Inc. filed Amendment No. 1 to its Form 8-K to correct the Date of Report on the cover page to February 9, 2026. The filing restates Item 1.01 in its entirety to clarify that the company entered into an Amended Settlement Agreement with Silverback Capital Corporation on that date. This Amended Settlement Agreement modifies a previously referenced Original Settlement Agreement and constitutes the material definitive agreement reported under Item 1.01.
Medicure (OTCMKTS:MCUJF) and Wellgistics Health (NASDAQ:WGRX) Head to Head Analysis
Wellgistics Health and Kare PharmTech Execute Joint Venture Expanding Access to 200,000+ Patient Lives
Penny Stock Wellgistics Health Ends Silverback Deal, Cuts Dilution Risk
Short Interest in Wellgistics Health, Inc. (NASDAQ:WGRX) Rises By 219.6%
Why Are Shares Of Wellgistics Health Falling?
Wellgistics Health Inc. Signs $105,000,000 Letter of Intent to Evaluate Potential Acquisition of Neuritek Therapeutics, Inc. which is Pioneering Innovative Therapies for Neurological and Psychiatric Disorders
Wellgistics Management Converts $2 Million in Deferred Compensation into Equity at $0.20 per Share
Wellgistics President Releases Letter to Shareholder on Emerging Patient Care-Centric Strategic Direction
Wellgistics Strengthens PharmacyChain(TM) with Insurance Eligibility & Benefits Verification Capabilities
Wellgistics Targets $70B Market Breakthrough Addressing Ozempic / GLP-1 Muscle Loss with Forzet(TM)
Wellgistics Health Selects Top Five Blockchain Platforms to Initiate Patent Protected PharmacyChain(TM) Smart Contracts-enabled Pharmaceutical Drug Tracking System to Support Industry-wide Serialization Mandate
Summit Therapeutics (NASDAQ:SMMT) and Wellgistics Health (NASDAQ:WGRX) Head to Head Comparison
Wellgistics Health Targets Expansion into $6.3 Billion Mental Health Software Market with Strategic Investment into Stealth Mental Health AI Startup
